Novartis OTC Stock Target Price and Analyst Consensus

NVSEF
 Stock
  

USD 81.00  3.85  4.54%   

Analysts of Novartis Ag Basl render investment recommendations by dissecting financials, analyzing earning calls, and talking to Novartis vendors, executives, and customers to validate their buy-or-sell advice. Unfortunately, the analyst consensus on Novartis is currently unavailable. Please use our comprehensive buy-or-sell advice module to check the latest Macroaxis investment opinion on Novartis
  
Refresh

About Novartis Target Price Projections

Novartis's target price is an analyst's projection of its future price. Price targets can be assigned to all types of securities, from complex investment products to otc stocks such as Novartis Ag Basl and even bonds. If the target price is unavailable, it is most likely because there were not enough analyst opinions to come up with a consensus estimate. When setting a price target estimate, an analyst is trying to determine what the OTC Stock is worth and where the price will be in a year from now. Generally, the target price of Novartis depends on its intrinsic valuation, beta (i.e., risk over market), and overall volatility. Most analysts publish their price targets in research reports on specific companies, along with their buy, hold, or sell recommendations. Stock price targets are often quoted in the financial news media. Macroaxis uses multiple feeds to provide overall target price projection for Novartis Ag Basl including its fundamental analysis.

Additional Novartis Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any OTC Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Novartis is a key component of Novartis valuation and have some predictive power on the future returns of a Novartis.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Novartis' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Novartis in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
78.7081.0083.30
Details
Intrinsic
Valuation
LowReal ValueHigh
79.1181.4183.71
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Novartis. Your research has to be compared to or analyzed against Novartis' peers to derive any actionable benefits. When done correctly, Novartis' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Novartis Ag Basl.

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Macroaxis Index
Invested few shares
Dividend Beast
Invested few shares
Insurance
Invested over 200 shares
Corona Opportunity
Invested over 300 shares
Additionally, see Macroaxis Advice on Novartis to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. Note that the Novartis Ag Basl information on this page should be used as a complementary analysis to other Novartis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Piotroski F Score module to get Piotroski F Score based on binary analysis strategy of nine different fundamentals.

Complementary Tools for Novartis OTC Stock analysis

When running Novartis Ag Basl price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
The data published in Novartis' official financial statements usually reflect Novartis' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Novartis Ag Basl. For example, before you start analyzing numbers published by Novartis accountants, it's critical to develop an understanding of what Novartis' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Novartis' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Novartis' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Novartis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Novartis Ag Basl. Please utilize our Beneish M Score to check the likelihood of Novartis' management to manipulate its earnings.